FDA is statutorily mandated to create these lists and issued a Proposed Rule on March 20, 2024, with comments being due by June 18, 2024
Shaman AM, Bain SC, Bakris GL et al (2022) Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
Regardless of the inconclusive scientific findings on GLP-1 alternative supplementation, countless users of these formulas have glowing anecdotal reviews, citing experiences of weight loss, reduced cravings, more energy, and improved digestion
The study followed patients from the start of treatment use to an outcome event defined as emigration, death, or end of study period
GROMADA J, HOLST J J, RORSMAN P.Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 [J]